Reuters
24 Jun 2026, 01:38 UTC · 2h ago
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
24 Jun 2026, 01:38 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
Abbisko Therapeutics has entered into a strategic research collaboration and license agreement with Eli Lilly. — Partnerships with major pharmaceutical firms like Eli Lilly typically provide significant validation of a biotech's pipeline and offer substantial financial inflows.
+0.60Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
[mutual] Eli Lilly entered into a strategic research collaboration and license agreement with Abbisko Therapeutics, a unit of Abbisko Cayman.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
11h ago
